BIVI
Biovie Inc
NASDAQ · Biotechnology
$1.13
+0.07 (+6.60%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 9.45M | 8.50M | 8.91M |
| Net Income | 239.2K | 243.9K | 245.4K |
| EPS | — | — | — |
| Profit Margin | 2.5% | 2.9% | 2.8% |
| Rev Growth | +19.1% | +23.4% | +6.1% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 2.36M | 2.23M | 2.43M |
| Total Equity | 3.96M | 4.02M | 4.56M |
| D/E Ratio | 0.60 | 0.55 | 0.53 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 403.0K | 435.3K | 434.6K |
| Free Cash Flow | 313.2K | 273.2K | 249.3K |